The Efficacy and Safety of a Selective Estrogen Receptor Beta Agonist (LY500307) for Negative Symptoms and Cognitive Impairment Associated With Schizophrenia
Phase of Trial: Phase II
Latest Information Update: 04 Jul 2019
At a glance
- Drugs Erteberel (Primary) ; Antipsychotics
- Indications Schizophrenia
- Focus Therapeutic Use
- 24 Jun 2019 Status changed from recruiting to discontinued.
- 31 Aug 2018 Biomarkers information updated
- 09 Oct 2017 Planned End Date changed from 1 Jul 2017 to 1 Jul 2018.